It was at that point that a doctor confirmed my suspicions: I had polyendocrine metabolic ovarian syndrome or PMOS (formerly known as PCOS), a hormonal condition affecting the ovaries, resulting in symptoms like acne, excess facial hair growth, androgenic alopecia, and, in my case, weight gain
These interactions occur when GLP-1 medications affect the absorption or effectiveness of other drugs, often due to delayed gastric emptying
Triple agonists add glucagon receptor activation, which: Increases resting energy expenditure by 8% to 12% (Jall et al., Diabetes Care 2024) Promotes hepatic fat oxidation and reduces steatosis May offset some of the lean mass loss seen with GLP-1 monotherapy (early signal, not yet confirmed in long-term trials) The weight loss ceiling for retatrutide appears to be 24% to 26% based on phase 3 data, though long-term real-world outcomes are not yet available
10.1016/j.ejphar.2024.176440 21 EspinosaD
CareFirst large-group formulary Tier 2/4 (where applicable) CareFirst large-employer commercial members can access Wegovy at Tier 2 or Tier 4 with prior authorization
"There are allowances for doctors to make their own decisions backed up by robust evidence to prescribe unapproved products to their patients," the TGA's chief medical adviser Robyn Langham said
.webp)
